Acta Medica Iranica 2018. 56(1):43-48.

The Follow-Up Role of the Vestibular Evoked Myogenic Potential Test in Meniere’s Disease
Nasrin Yazdani, Farzaneh Nejadian, Nima Rezazadeh, Reza Hoseinabadi, Ebrahim Karimi, Reza Gharibi, Sasan Dabiri


Despite some proposed roles for the diagnostic impact of the cervical vestibular evoked myogenic potential test in the patients with Meniere’s disease, the role of this test as an objective instrument in following up the patients with Meniere’s disease who underwent. Intratympanic steroid injection is not cleared. In a prospective study, thirty-one adult patients with definite one-sided Meniere's disease with vertigo as main complaint refractory to medical treatments for three months, were selected. Patients underwent three times of intratympanic dexamethasone injection with one-week intervals. We performed cervical vestibular evoked myogenic potential test at first and four weeks after the last injection for all participants. We followed the patients for one year. The study results were analyzed with the chi-square test. Cervical vestibular evoked myogenic potential test could not be recorded in 26 patients (83.9%), and the test results were abnormal in the remaining 5 patients. The results were abnormal in the healthy ear of 32.3% of the patients. Despite the clinical improvement of the symptoms after intratympanic injection, the test results were not changed. Cervical vestibular evoked myogenic potential test could not be recorded in the majority of the patients with Meniere's disease; while it is usually recorded in normal ears. On the other hand, results of the cervical vestibular evoked myogenic potential test do not change during the early phase after treatment and could not be a good option for follow up and evaluating the response in this situation.


Meniere’s disease; cVEMP test; Intratympanic injection; Dexamethasone; Follow up

Full Text:



Seo, YJ, Kim J, Choi JY, Lee WS. Visualization of endolymphatic hydrops and correlation with audio-vestibular functional testing in patients with definite Meniere's disease. Auris Nasus Larynx 2012;40:167-72.

Paparella MM, Djalilian HR. Etiology, pathophysiology of symptoms, and pathogenesis of Meniere's disease. Otolaryngol Clin North Am 2002;35:529-45

Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease. Otolaryngol Head Neck Surg 1995;113:181-5

Thorp MA, Shehab ZP, Bance ML, Rutka JA, AAO-HNS Committee on Hearing and Equilibrium. The AAO-HNS Committee on Hearing and Equilibrium Guidelines for the diagnosis and evaluation of therapy in Menieres disease: have they been applied in the published literature of the last decade? Clin Otolaryngol Allied Sci 2003;28:173-6.

Katayama N, Yamamoto M, Teranishi M, Naganawa S, Nakata S, Sone M, et al. Relationship between endolymphatic hydrops and vestibular-evoked myogenic potential. Acta Otolaryngol 2010;130:917-23.

Kim-Lee Y, Ahn JH, Kim YK, Yoon TH. Tone burst vestibular evoked myogenic potentials: diagnostic criteria in patients with Meniere's disease. Acta Otolaryngol 2009;129:924-8.

Celis-Aguilar E, Hinojosa-González R, Vales-Hidalgo O, Coutinho-Toledo H. Refractory episodic vertigo: role of intratympanic gentamicin and vestibular evoked myogenic potentials. Braz J Otorhinolaryngol 2016;82:668-73.

Sajjadi H, Paparella MM. Meniere's disease. Lancet 2008;372:406-14.

Claes J, Van de Heyning PH. Medical treatment of Meniere's disease: a review of literature. Acta Otolaryngol Suppl 1997;117:37-42.

Derebery MJ. Allergic and immunologic aspects of Meniere's disease. Otolaryngol Head Neck Surg 1996;114:360-5.

Barrs DM, Keyser JS, Stallworth C, McElveen JT Jr. Intratympanic steroid injections for intractable Meniere's disease. Laryngoscope 2001;111:2100-4.

Dabiri S, Yazdani N, Esfahani M, Tari N, Adil S, Mahvi Z, et al. Analysis of saccular function with vestibular evoked myogenic potential test in Meniere's disease. Acta Med Iran 2017;55:123-7.

Wladislavosky-Waserman P, Facer GW, Mokri B, Kurland LT. Meniere's disease: A 30-Year epidemiologic and clinical study in Rochester, Mn, 1951-1980. Laryngoscope, 1984;94:1098-102.

Paparella MM. Pathogenesis and pathophysiology of Meniere's disease. Acta Otolaryngol Suppl 1991;111:26-35.

de Waele C, Tran Ba Huy P, Diard JP, Freyss G, Vidal PP. Saccular dysfunction in Ménière's patients. A vestibular-evoked myogenic potential study. Ann N Y Acad Sci 1999;871:392-7.

Young YH, Huang TW, Cheng PW. Assessing the stage of Meniere's disease using vestibular evoked myogenic potentials. Arch Otolaryngol Head Neck Surg 2003;129:815-8.

Sennaroğlu L, Dini FM, Sennaroğlu G, Gursel B, Ozkan S. Transtympanic dexamethasone application in Meniere's disease: an alternative treatment for intractable vertigo. J Laryngol Otol 1999;113:217-21.

Boleas-Aguirre MS, Lin FR, Della Santina CC, Minor LB, Carey JP. Longitudinal results with intratympanic dexamethasone in the treatment of Menieres disease. Otol Neurotol 2008;29:33-8.

Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, Pane-Pianese C, Ríos-Castañeda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Menieres disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005;133:285-94.

Kyrodimos E, Aidonis I, Skalimis A, Sismanis A. Use of Glasgow Benefit Inventory (GBI) in Meniere's disease managed with intratympanic dexamethasone perfusion: Quality of life assessment. Auris Nasus Larynx 2011;38:172-7.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.